Skip to Content
Merck
All Photos(1)

Key Documents

SML1916

Sigma-Aldrich

Marizomib

≥95% (HPLC), (Salinospora tropica)

Synonym(s):

(1R,4R,5S)-4-(2-Chloroethyl)-1-[(S)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, NPI-0052, Salinosporamide A

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H20ClNO4
CAS Number:
437742-34-2
Molecular Weight:
313.78
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

biological source

(Salinospora tropica)

Assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

shipped in

wet ice

storage temp.

−20°C

InChI

1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1

InChI key

NGWSFRIPKNWYAO-SHTIJGAHSA-N

Application

Marizomib has been used as a proteasome inhibitor:
  • to study its effects on glioblastoma cell lines
  • to analyze its effects on the aging of killifish brain
  • to test its effect on protein kinase B (PKB/AKT) levels in multiple myeloma cells

Biochem/physiol Actions

Marizomib a natural product is a marine-derived β-lactone-γ-lactam. It shows therapeutic effects against hematologic and solid tumor malignancies.. It is involved in the activation of caspase-3,-8, and -9, increases the reactive oxygen species (ROS) and promotes apoptosis. Marizomib can cross the blood-brain barrier and might have the potential to treat primary brain tumors. It possesses anti-tumor properties.
Marizomib is a second generation proteasome inhibitor with anti-cancer activity. Marizomib binds irreversibly and potently inhibits all three 20S proteasome subunits.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kaijun Di et al.
Neuro-oncology, 18(6), 840-848 (2015-12-19)
The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential
Nancy Levin et al.
British journal of haematology, 174(5), 711-720 (2016-05-11)
Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in
A M Rajan et al.
Blood cancer journal, 6(7), e451-e451 (2016-07-30)
The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service